However, despite examining the issue for several years, India’s drug regulator has not disclosed any final, reasoned or publicly available decision on the matter, the petition alleged.The plea further stated that on April 24, 2025, DTAB referred the matter to a further committee and an ICMR study. It added that the three-month deadline for submitting the report, fixed by the Union government on July 24, 2025, expired around October 24, 2025.However, as recently as October 7, 2026, CDSCO maintained that the report was awaited and the matter remained under review.“The medicine is cheap, widely available and often bought without a prescription, so the people who bear the burden of an unresolved question are largely those least able to find or pay for other care.
Regulators in the United States, the European Union, Australia, Canada, the United Kingdom and Singapore each reached some decision on Ranitidine after the 2019 alerts,” the petition said.The matter will be heard next in February.